美國Ventana Medical Systems www.ventana.com
Ventana Medical的臨床診斷業(yè)務(wù)主要基于人體組織標(biāo)本的分析，特別是在腫瘤和傳染病的診斷領(lǐng)域是領(lǐng)先的。

2007年羅氏(Roche )30億美元收購美國Ventana Medical

Ventana Medical Systems, Inc. (“VMSI”) (SIX: RO, ROG)(OTCQX:RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA solutions are used in clinical histology and drug development research laboratories worldwide. The company’s intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to reduce errors, support diagnosis and inform treatment decisions for anatomic pathology professionals. Together with Roche, VMSI is driving Personalized Healthcare through accelerated drug discovery and the development of “companion diagnostics” to identify the patients most likely to respond favorably to specific therapies. 

Our culture of constant innovation fuels our vision: to empower our customers by providing the highest quality, most innovative cancer diagnostic solutions. We are passionate in our pursuit of diagnostic leadership because when we empower pathology professionals, we improve the outlook for patients.
Ventana Medical Systems, Inc., a member of the Roche Group, is a world leader and innovator of tissue-based diagnostic solutions for patients worldwide.
Passionately pursuing their mission to improve the lives of all patients afflicted with cancer, the people of Ventana discover, develop, and deliver medical diagnostic systems and biopsy based cancer tests that are shaping the future of healthcare. As the leading supplier of cancer diagnostic systems to the pathology market, Ventana manufactures over 200 cancer tests with related instruments right here in southern Arizona for 56 countries, and most importantly, for 4 million people afflicted with cancer yearly around the world. Ventana products provide healthcare professionals with a total solution for all critical steps involved in the analysis of tissue biopsies. This pioneering company also offers premier workflow solutions to improve laboratory efficiency and preserve patient safety.
Linking the most accurate diagnosis with the most targeted and relevant therapeutic is the essence of Personalized Healthcare. Clearly, the value of the Personalized Healthcare approach is rooted in positive outcomes for the patient—saving lives and improving the quality of life. Ventana focuses on accelerating the discovery and development of new cancer tests that allow pathologists to analyze patient biopsies at the molecular level to help determine the best course of therapy for each individual patient. As a member of the Roche Group, drawing on powerful partnerships with world-class scientific institutes, there is no company in the world in a better position to make this approach a reality.